Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Plus Etoposide and Carboplatin in First-line ES-SCLC
NCT04684017Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- May 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in small cell lung cancer (SCLC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04684017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684017.